Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when JNJ files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsJ&J proposes $5.5B settlement to resolve 76,000 ovarian talc claims, requires 95% participation
Filed July 28, 2026 · Period ending July 27, 2026 · ~1 min read
Key Changes
-
high
J&J commits $5.5B to settle remaining ovarian talc litigation covering ~76,000 claims, with first payment of up to $3B in 2027 and no further payments before 2028, contingent on 95% plaintiff participation.
Exhibit 99.1 view on EDGAR → -
high
MDL court on July 22, 2026 ordered plaintiffs to justify why claims should not be dismissed for inability to prove specific causation, after plaintiffs withdrew experts in two bellwether cases following hearing that exposed methodological flaws.
Exhibit 99.1 view on EDGAR → -
medium
Settlement would complete talc litigation resolution after J&J previously settled ~95% of mesothelioma lawsuits, all state consumer protection claims, and all talc-supplier disputes.
Exhibit 99.1 view on EDGAR → -
medium
J&J retained all talc liabilities and indemnifies Kenvue for any costs from U.S. and Canada talc litigation following the August 2023 consumer health separation.
Exhibit 99.1 view on EDGAR →
Summary
Johnson & Johnson announced a proposed $5.5 billion settlement to resolve approximately 76,000 remaining ovarian cancer talc claims, contingent on participation by plaintiff firms representing at least 95% of claims. The settlement calls for an initial payment of up to $3 billion in 2027, with no additional payments due before 2028.
The proposal follows a favorable July 22, 2026 MDL court ruling that ordered plaintiffs to justify why their claims should not be dismissed for inability to prove specific causation, after plaintiffs withdrew their expert witnesses in two bellwether cases when a hearing exposed methodological flaws in their opinions.
For retail holders, this settlement would provide clarity on J&J's remaining talc litigation exposure and establish a defined payment schedule. The $5.5 billion commitment represents the company's assessment of resolution cost for the ovarian cancer claims, which complements prior settlements covering approximately 95% of mesothelioma cases and all state consumer protection claims. The 95% participation threshold creates execution risk—if insufficient plaintiffs agree, the settlement could fail and litigation would continue. The favorable causation ruling strengthened J&J's negotiating position but does not eliminate the claims. All talc liabilities remain with J&J following the 2023 Kenvue separation, with J&J indemnifying Kenvue for any related costs.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Complements the progress the Company already has made to resolve the talc litigation, including previously settling about 95% of filed mesothelioma lawsuits, all State consumer protection claims, and all talc-supplier disputes.
J&J has already resolved substantial portions of its talc litigation portfolio prior to this announcement. The company previously settled approximately 95% of filed mesothelioma lawsuits, all state consumer protection claims, and all disputes with talc suppliers. This ovarian cancer settlement would complete the resolution of the remaining major talc litigation exposure.
Added in current filing · view on EDGAR →
Prior to its separation, Johnson & Johnson agreed to retain all the talc-related liabilities and indemnify Kenvue for any and all costs—arising from litigation in the United States and Canada.
J&J retained all talc-related liabilities when it separated its consumer health business (Kenvue) in August 2023. J&J agreed to indemnify Kenvue for any costs arising from talc litigation in the United States and Canada, meaning this settlement and any related costs remain solely with J&J and do not affect Kenvue.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 29, 2026 · How we verify